| Primary |
| Essential Thrombocythaemia |
22.2% |
| Polycythaemia Vera |
14.1% |
| Chronic Myeloid Leukaemia |
13.1% |
| Sickle Cell Anaemia |
5.9% |
| Thrombocythaemia |
4.9% |
| Product Used For Unknown Indication |
4.2% |
| Platelet Count Increased |
3.6% |
| Thalassaemia Beta |
3.6% |
| Acute Myeloid Leukaemia |
3.3% |
| Thrombocytosis |
3.3% |
| Myeloproliferative Disorder |
2.9% |
| Polycythaemia |
2.9% |
| Glioblastoma |
2.6% |
| Hypertension |
2.6% |
| Depression |
2.3% |
| Myelofibrosis |
2.3% |
| Multiple Myeloma |
2.0% |
| Skin Ulcer |
1.6% |
| Breast Cancer |
1.3% |
| Leukaemia |
1.3% |
|
| Skin Ulcer |
12.3% |
| Death |
11.4% |
| Respiratory Failure |
7.0% |
| Acute Myeloid Leukaemia |
6.1% |
| Thrombocytopenia |
6.1% |
| White Blood Cell Count Abnormal |
5.3% |
| Azoospermia |
4.4% |
| Pregnancy |
4.4% |
| Serum Ferritin Increased |
4.4% |
| Thrombosis |
4.4% |
| Tumour Lysis Syndrome |
4.4% |
| Haemorrhage |
3.5% |
| Platelet Count Increased |
3.5% |
| Pyrexia |
3.5% |
| Rash |
3.5% |
| Transient Ischaemic Attack |
3.5% |
| Vomiting |
3.5% |
| White Blood Cell Count Decreased |
3.5% |
| Adverse Drug Reaction |
2.6% |
| Cytogenetic Analysis Abnormal |
2.6% |
|
| Secondary |
| Essential Thrombocythaemia |
32.6% |
| Chronic Myeloid Leukaemia |
12.2% |
| Hiv Infection |
11.9% |
| Glioblastoma Multiforme |
6.3% |
| Squamous Cell Carcinoma |
5.2% |
| Hypertension |
4.6% |
| Acute Myeloid Leukaemia |
4.2% |
| Drug Use For Unknown Indication |
3.6% |
| Depression |
2.3% |
| Neoplasm Malignant |
2.3% |
| Head And Neck Cancer |
2.3% |
| Acquired Immunodeficiency Syndrome |
1.9% |
| Product Used For Unknown Indication |
1.7% |
| Hyperuricaemia |
1.6% |
| Migraine |
1.5% |
| Antiretroviral Therapy |
1.4% |
| Pain |
1.2% |
| Sickle Cell Anaemia |
1.2% |
| Premedication |
1.1% |
| Astrocytoma |
1.0% |
|
| White Blood Cell Count Decreased |
12.8% |
| Neoplasm Malignant |
9.7% |
| Thrombocytopenia |
9.7% |
| Pneumonia |
9.2% |
| Sepsis |
5.6% |
| Vomiting |
5.6% |
| Pericardial Effusion |
5.1% |
| Arrhythmia |
4.6% |
| Dehydration |
4.1% |
| Death |
3.6% |
| Gastrointestinal Haemorrhage |
3.6% |
| Nausea |
3.6% |
| Vasculitis Cerebral |
3.6% |
| Epistaxis |
3.1% |
| Mouth Ulceration |
3.1% |
| Pancytopenia |
3.1% |
| Portal Vein Thrombosis |
2.6% |
| Pulmonary Oedema |
2.6% |
| Pyrexia |
2.6% |
| Respiratory Failure |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.5% |
| Chronic Myeloid Leukaemia |
10.4% |
| Drug Use For Unknown Indication |
8.8% |
| Sickle Cell Anaemia |
8.5% |
| Hypertension |
8.2% |
| Acute Myeloid Leukaemia |
6.8% |
| Pain |
5.2% |
| Prophylaxis |
4.6% |
| Iron Overload |
4.4% |
| Myelofibrosis |
3.6% |
| Essential Thrombocythaemia |
3.3% |
| Myelodysplastic Syndrome |
2.7% |
| Pustular Psoriasis |
1.9% |
| Nausea |
1.8% |
| Depression |
1.7% |
| Osteoporosis |
1.7% |
| Atrial Fibrillation |
1.6% |
| Pulmonary Hypertension |
1.5% |
| Stem Cell Transplant |
1.5% |
| Diabetes Mellitus |
1.4% |
|
| White Blood Cell Count Increased |
10.4% |
| Death |
9.9% |
| Vomiting |
9.9% |
| Sickle Cell Anaemia With Crisis |
9.7% |
| Thrombocytopenia |
8.6% |
| Pneumonia |
6.4% |
| Weight Decreased |
6.0% |
| Rash |
4.4% |
| White Blood Cell Count Decreased |
4.4% |
| Drug Ineffective |
4.0% |
| T-cell Lymphoma |
3.3% |
| Tumour Lysis Syndrome |
3.3% |
| Pyrexia |
3.1% |
| Acute Myeloid Leukaemia |
2.9% |
| Respiratory Failure |
2.6% |
| Renal Failure Acute |
2.4% |
| Nausea |
2.2% |
| Pain In Extremity |
2.2% |
| Renal Failure |
2.2% |
| Oedema Peripheral |
2.0% |
|
| Interacting |
| Sickle Cell Anaemia |
18.8% |
| Hypertension |
12.5% |
| Iron Overload |
12.5% |
| Thrombosis Prophylaxis |
12.5% |
| Convulsion |
6.3% |
| Infection Prophylaxis |
6.3% |
| Ischaemic Heart Disease Prophylaxis |
6.3% |
| Platelet Count Increased |
6.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
6.3% |
| Tachycardia |
6.3% |
| Thalassaemia Beta |
6.3% |
|
| Drug Interaction |
20.0% |
| Liver Function Test Abnormal |
20.0% |
| Swollen Tongue |
20.0% |
| Transaminases Increased |
20.0% |
| Weight Increased |
20.0% |
|
